Core Insights - Moberg Pharma AB has entered into an exclusive licensing agreement with Karo Healthcare AB for the commercialization of MOB-015 (Terclara®) in Europe, covering 19 European markets [1][2][11] - The partnership aims to leverage the established Lamisil® brand for a coordinated launch across key EU markets, enhancing market presence and distribution capabilities [3][4][9] Market Opportunity - The agreement encompasses a total population of approximately 500 million people, including major EU countries and the UK, providing significant market potential for MOB-015 [2] - Karo Healthcare will handle marketing, distribution, and sales, allowing Moberg Pharma to focus on other territories, particularly the U.S. [10] Product Details - MOB-015/Terclara® is a next-generation topical formulation of terbinafine, designed to treat nail fungus with a mycological cure rate of 76% in registration studies, comparable to oral treatments [6] - The product aims to address the risks associated with oral treatments, such as drug interactions and liver damage, by providing a safer topical alternative [6] Regulatory and Launch Strategy - The use of the Lamisil® brand for MOB-015 requires approval from national health authorities, which will influence the timing of the product launch [7] - Both companies plan to initiate the launch as soon as possible and will also work to expand marketing authorizations to additional countries [8] Strategic Partnership - Karo Healthcare, backed by KKR, has a strong commercial presence in Europe and established distribution channels, enhancing the product's market entry [9][10] - The collaboration is expected to accelerate Moberg Pharma's commercial expansion and establish MOB-015/Terclara® as a market leader in nail fungus treatment across Europe [11]